Suvratoxumab
Based on 1 Customer Validation
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394).
For research use only. We do not sell to patients.
- Purity : 98.79%
- CAS No.: 1629620-18-3
- Molecular Weight:145.54 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
alpha toxin
In Vivo
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis reduces pulmonary damage and increases macrophage phagocytosis in mice[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis improves the effectiveness of antibiotic (vancomycin or linezolid) treatment in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1].
-
Dosage:5, 15, 45 mg/kg
-
Administration:Intraperitoneal injection; single
-
Result:Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU.
-
Animal Model:Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1].
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection; single
-
Result:Prophylaxis protected the lungs of S. aureus-infected immunocompromised mice from α toxin-mediated damage.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
3920722 [NCBI]
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1629620-18-3
-
Appearance Liquid
-
Molecular Weight 145.54 kDa
-
Color Colorless to light yellow
-
SMILES
[Suvratoxumab]
-
Synonyms
MEDI4893
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. [Content Brief]
[2]. Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16. [Content Brief]
[3]. Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Suvratoxumab Related Classifications
HY-P99583 Related Classifications
Powered by Bioz